News release: Firm to host panel of experts at BIO2009 International Convention in Atlanta

"How to Grow and Retain Your Biotech Dream Team" is topic

Contact: Christine Leon, Director of Communications
Tel: +1 918 949 3609      
Fax: +1 770 396 6693

May 12, 2009

Moderator | J. Larry Tyler, FACHE, FAAHC,  FHFMA, CMPE

J. Larry Tyler, Chairman and CEO of Tyler & Company, is originally from Washington, a small, historic town in eastern Georgia. He began his professional career on the audit staff of Price Waterhouse & Co. and became a Certified Public Accountant in 1975. Three years later, he founded Tyler & Company, which conducts executive-level searches for the healthcare and life science industries. Tyler & Company is repeatedly named by Executive Recruiter Newsas one of the 40 largest search firms in the nation and by Modern Healthcaremagazine as one of the top 20 in healthcare. He serves on the Board of Signium International, a consortium of executive search firms with more than 40 offices in 25-plus countries.

Tyler is a Fellow of the American Association of Healthcare Consultants, the American College of Healthcare Executives and the Healthcare Financial Management Association. He is a Certified Medical Practice Executive of the American College of Medical Practice Executives, and a member of the American Institute of CPAs and the Georgia Society of CPAs.

Tyler is an adjunct professor in health administration of the University of Colorado at Denver and the University of Alabama at Birmingham. He has a bachelor’s in industrial management from Georgia Institute of Technology in Atlanta, and a master’s in professional accountancy from Georgia State University.

Panelist | Lisa Kelly-Croswell, MHRIR

Lisa Kelly-Croswell is Senior Vice President of Human Resources at Vertex Pharmaceuticals and has 18 years of experience in a wide range of global and domestic HR leadership roles. Prior to joining Vertex, Kelly-Croswell was the Vice President of Human Resources at Nitromed, Inc., a biopharmaceutical firm in Lexington, Mass. Before that, she was Senior Vice President of Healthcare and Service Operations at CIGNA.

Kelly-Croswell spent a large portion of her career in other world-class HR organizations including Monsanto Company and Frito-Lay, Inc. She has broad HR experience, including generalist work in research and development, manufacturing, regional and local sales and headquarters groups. She has also held specialist assignments in organizational development, labor relations and staffing.

Kelly-Croswell held an expatriate assignment based in Singapore, leading HR for Southeast Asia, where she had responsibility for integrated businesses in Thailand, Vietnam, Malaysia, the Philippines and Indonesia.  She also led HR strategy for manufacturing across Asia Pacific. She attended the University of Illinois at Urbana-Champaign where she received a bachelor’s in finance and a master’s in labor and industrial relations. 

Panelist | Mark Lyles, M.D., MBA

Mark Lyles has worked at Amicus Therapeutics since May 2006, and he currently holds the role of Senior Director of Medical Affairs. Prior to joining Amicus, Lyles served eight years on the Internal Medicine faculty at the Medical University of South Carolina in Charleston. In addition to seeing patients and teaching medical students and residents, Lyles held numerous administrative roles, including the position of Senior Associate Dean for Clinical Affairs in the College of Medicine and Chairman of the health system’s Pharmacy and Therapeutics Committee.

A board-certified internist, Lyles earned his medical degree from the Medical University of South Carolina in Charleston. He completed a fellowship in Quality Management and Managed Care at the University of Pennsylvania Health System. He holds an MBA in healthcare management from the Wharton School.

Panelist | Shawn Patrick O’Brien

Shawn Patrick O’Brien joined Profectus BioSciences, Inc. in January 2008, and assumed the role of President and CEO. O’Brien has worked in the biopharmaceutical industry since 1983 and most recently served as President and CEO of Solstice Neurosciences, Inc., a private emerging biotech specialty pharmaceutical company specializing in neurological diseases and movement disorders. During his tenure at Solstice, O’Brien built the business platform, increased U.S. sales by 90 percent, opened the E.U. market with a new partner, secured key intellectual property, expanded the clinical development program and secured $85 million in private funding.

Previously, O’Brien worked with AstraZeneca USA as Vice President of Commercial Operations for Emerging Brands, and as Vice President and Therapy Area Leader for the Respiratory and Inflammation Business Unit. As the business area leader, he was responsible for research and development, marketing and sales of the $1 billion U.S. respiratory franchise. From 1987 to 2001, he held various management positions at AstraZeneca in global and domestic roles in the United States, Canada and the United Kingdom. Earlier, he was with the Upjohn Company of Canada. O’Brien is a graduate of the University of Western Ontario.

Panelist | Chad Womack, Ph.D.

Chad Womack is a principal in the Emerging Technology Consortium based in Washington, D.C. and is Founder, President and Executive Director of the Philadelphia Biotechnology and Life Sciences Institute, a nonprofit initiative founded to address human capital/workforce development and bio-entrepreneurship issues for the bio-life science industry in the greater Philadelphia area. Womack has served as Vice President for Educational and Training Initiatives at the University City Science Center.  He also is the co-founder of NanoVec, Inc. and has served as its President and Chief Scientific Officer since its inception.  He is a co-founder, President and Chair of the National Association for Blacks in Bio, a nonprofit organization dedicated to building a diverse community within the biotechnology and life science industry. 

Womack held the position of Assistant Professor (tenure-track) at the Howard University College of Medicine in Washington, D.C., and completed several research fellowships at the National Institutes of Health. He earned his doctorate in biomedical sciences from Morehouse School of Medicine while completing graduate thesis research at Harvard AIDS Institute and the Harvard School of Public Health in Boston. Womack completed a year of post-doctoral research at the Harvard AIDS Institute, where he continued his international HIV/AIDS research and collaborations in India. He is a graduate of Morehouse College, earning his bachelor’s with honors in biology and minors in chemistry and applied physics.

Panelist | Michael Young, M.D., Ph.D., MBA

Michael Young is a clinical development and regulatory expert who has run his own consulting business for the last eight years. In this regard, he has been brought into companies as the acting senior manager of clinical and regulatory functions in Europe and the United States. He has been the Vice President for Clinical Research Europe for Chiron, and in 2008, he was the Executive Vice President of Clinical Development for Nucleonics, Inc. In his consulting capacity, he also has advised on numerous strategic actions by a number of healthcare companies. He has supervised the submission of INDs and NDAs and has led meetings with FDA-reviewing divisions and with office-level management at the agency. In his 25 years of management within the healthcare field, he has had direct responsibility for clinical research and development, pre-clinical development, product formulation and regulatory affairs within a number of pharmaceutical companies. 

Young previously was Executive Vice President and Chief Scientific Officer of Medeva PLC; Corporate Director, Worldwide Regulatory and Clinical Development, for The Proctor & Gamble Company; Vice President, Worldwide Regulatory Affairs and U.S. Clinical Development at SmithKline and French Laboratories; and Executive Vice President, Scientific Affairs at Astra Pharmaceuticals, Inc. He began his career in the pharmaceutical industry as Associate Medical Director at Delbay Pharmaceuticals, a joint venture of Bayer AG and Schering Plough Corp.

Young received a bachelor’s in chemistry and pure mathematics followed by a doctorate in chemistry from the University of Wales. He was a post-doctoral research fellow at the Retina Foundation of the Massachusetts Eye & Ear Hospital. He also received an M.B., B.Ch. with a distinction in biochemistry from the Welsh National School of Medicine, where he was awarded the McKlintock Prize in Clinical Cancer. He completed his internship at University Hospital, Cardiff, and was a resident in pediatrics. Young earned his MBA from Columbia School of Business in New York.